ALiEM - Pharm Pearls

NOVEMBER 1, 2023

McGraw-Hill Education; 2019 Madiwale T, Liebelt E. Hypersensitivity reactions to rifampin: Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease.

Clinical Pharmacology 161

Clinical Pharmacology Dosage Compounding 161

RX Note

APRIL 16, 2023

External Links Disease Management: A Guide to Clinical Pharmacology, 2016 Rang & Dale’s Pharmacology, 2019 Nonetheless, domperidone should be avoided in patients with conduction disorders or cardiac disease due to its association with Q-T interval prolongation.

Clinical Pharmacology 52

Clinical Pharmacology 52

PharmD Live

MAY 30, 2024

British Journal of Clinical Pharmacology, 67(6), 689–700. Retrieved from British Journal of Clinical Pharmacology Jyrkka, J., British Journal of Clinical Pharmacology, 74(4), 627–633. Retrieved from British Journal of Clinical Pharmacology Family Caregiver Alliance. A., & O’Mahony, M.

Clinical Pharmacology 119

Clinical Pharmacology Hospitals Long-Term Care Facilities Dosage 119

RX Note

JANUARY 21, 2023

Adverse Drug Reaction Drug Induced Diseases, 2018 Meyler's Side Effects of Drugs, 2015 Antibiotics The Sanford Guide to Antimicrobial Therapy, 2022 Breastfeeding Briggs' Drugs in Pregnancy and Lactation, 2021 Hale's Medications and Mothers' Milk, 2021 Clinical Practice Applied Therapeutics, 2018 Conn’s Current Therapy, 2022 Current Medical Diagnosis (..)

Compounding 40

Compounding Community Pharmacies Clinical Pharmacology Dosage 40

pharmaphorum

JANUARY 29, 2021

Researchers from the University of East Anglia (UEA) in collaboration with Boots UK and Leiden University analysed 2019 NHS dispensing data across the UK. This would have reduced their risk of side effects and could have led to better clinical outcomes.”. Estimating the potential impact of implementing pre?emptive

Clinical Pharmacology 98

Clinical Pharmacology Community Pharmacies 98

pharmaphorum

MARCH 11, 2022

Vraylar, sold in some markets as Reagila, was first approved in 2015 for schizophrenia and bipolar disorder, with its label extended in 2017 to include maintenance treatment of schizophrenia and again in 2019 for bipolar depression.

Clinical Pharmacology 52

Clinical Pharmacology Labelling 52

European Pharmaceutical Review

MAY 2, 2023

In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.

Clinical Pharmacology 105

Clinical Pharmacology Compounding Communication Pharmaceutical Companies 105